[go: up one dir, main page]

MX2021002180A - Composiciones de inhibidores del receptor de quimiocina c-x-c tipo 4 (cxcr4) y metodos de preparacion y uso. - Google Patents

Composiciones de inhibidores del receptor de quimiocina c-x-c tipo 4 (cxcr4) y metodos de preparacion y uso.

Info

Publication number
MX2021002180A
MX2021002180A MX2021002180A MX2021002180A MX2021002180A MX 2021002180 A MX2021002180 A MX 2021002180A MX 2021002180 A MX2021002180 A MX 2021002180A MX 2021002180 A MX2021002180 A MX 2021002180A MX 2021002180 A MX2021002180 A MX 2021002180A
Authority
MX
Mexico
Prior art keywords
methods
compositions
preparation
cxcr4 inhibitors
cxcr4
Prior art date
Application number
MX2021002180A
Other languages
English (en)
Inventor
Karel Marie Joseph Brands
Original Assignee
X4 Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by X4 Pharmaceuticals Inc filed Critical X4 Pharmaceuticals Inc
Publication of MX2021002180A publication Critical patent/MX2021002180A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a composiciones y métodos de uso para tratar, prevenir, o aliviar una enfermedad, trastorno, o condición asociada con un receptor de quimiocina tal como CXCR4.
MX2021002180A 2018-08-31 2019-08-30 Composiciones de inhibidores del receptor de quimiocina c-x-c tipo 4 (cxcr4) y metodos de preparacion y uso. MX2021002180A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862726010P 2018-08-31 2018-08-31
US16/215,963 US10548889B1 (en) 2018-08-31 2018-12-11 Compositions of CXCR4 inhibitors and methods of preparation and use
PCT/US2019/049065 WO2020047410A1 (en) 2018-08-31 2019-08-30 Compositions of cxcr4 inhibitors and methods of preparation and use

Publications (1)

Publication Number Publication Date
MX2021002180A true MX2021002180A (es) 2021-09-14

Family

ID=69230180

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021002180A MX2021002180A (es) 2018-08-31 2019-08-30 Composiciones de inhibidores del receptor de quimiocina c-x-c tipo 4 (cxcr4) y metodos de preparacion y uso.

Country Status (13)

Country Link
US (5) US10548889B1 (es)
EP (1) EP3843720A4 (es)
JP (2) JP7525903B2 (es)
KR (1) KR102908092B1 (es)
CN (1) CN112839649A (es)
AU (1) AU2019328530B2 (es)
BR (1) BR112021003467A2 (es)
CA (1) CA3110735A1 (es)
EA (1) EA202190377A9 (es)
IL (1) IL281082A (es)
MX (1) MX2021002180A (es)
SG (1) SG11202101814RA (es)
WO (1) WO2020047410A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3008272A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
JP6958820B2 (ja) 2015-12-14 2021-11-02 エックス４ ファーマシューティカルズ， インコーポレイテッド がんを処置する方法
JP7055380B2 (ja) 2015-12-22 2022-04-18 エックス４ ファーマシューティカルズ， インコーポレイテッド 免疫不全疾患を処置するための方法
US11337969B2 (en) 2016-04-08 2022-05-24 X4 Pharmaceuticals, Inc. Methods for treating cancer
WO2017223229A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
CN116554168B (zh) 2016-06-21 2025-09-23 X4制药有限公司 Cxcr4抑制剂及其用途
CN109641838A (zh) 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
US10548889B1 (en) * 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
US11878009B2 (en) * 2019-09-10 2024-01-23 Great Novel Therapeutics Biotech & Medicals Corporation Anticancer combination of chidamide and celecoxib salts
EP4117662A4 (en) * 2020-03-10 2024-04-03 X4 Pharmaceuticals, Inc. Methods for treating neutropenia
CN115894360B (zh) * 2021-09-30 2025-04-15 上海医药工业研究院 手性胺类化合物及其中间体的制备方法
MX2024004165A (es) * 2021-10-07 2024-05-10 X4 Pharmaceuticals Inc Sintesis de mavorixafor e intermediarios del mismo.
US20250041292A1 (en) * 2021-12-09 2025-02-06 X4 Pharmaceuticals, Inc. Methods for treating primary immunodeficiency
CN116789639A (zh) * 2022-03-14 2023-09-22 上海医药工业研究院有限公司 Mavorixafor的纯化方法、其盐及有关物质
WO2023240259A1 (en) * 2022-06-10 2023-12-14 X4 Pharmaceuticals, Inc. Treatments for conditions involving increased il-6 levels
WO2024216075A1 (en) * 2023-04-13 2024-10-17 X4 Pharmaceuticals, Inc. Synthesis of mavorixafor and intermediates thereof
WO2024216095A1 (en) * 2023-04-13 2024-10-17 X4 Pharmaceuticals, Inc. Synthesis of mavorixafor and intermediates thereof
WO2024216114A1 (en) * 2023-04-13 2024-10-17 X4 Pharmaceuticals, Inc. Synthesis of mavorixafor and intermediates thereof

Family Cites Families (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US4933447A (en) 1987-09-24 1990-06-12 Ss Pharmaceutical Co., Ltd. Quinoline derivatives
US5021409A (en) 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
US6001826A (en) 1989-12-21 1999-12-14 Anormed, Inc. Chemical compounds
GB9126677D0 (en) 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
GB9200245D0 (en) 1992-01-07 1992-02-26 British Bio Technology Compounds
US5235056A (en) 1992-04-22 1993-08-10 Ciba-Geigy Corporation Substituted 1-hydroxy-2,6-diaryl-4-piperidone ketals and polymer compositions stabilized therewith
GB9400411D0 (en) 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
GB9511357D0 (en) 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
US6506770B1 (en) 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
AU6887996A (en) 1995-09-01 1997-04-01 Washington University School Of Medicine Method of reducing neurotoxic injury with zinc chelators
PL329070A1 (en) 1996-03-22 1999-03-15 Du Pont Pharm Co Novel dissymetrical synthesis of r-alpha-propylpiperonylamine and its analoques
ES2182327T3 (es) 1997-06-02 2003-03-01 Janssen Pharmaceutica Nv Derivados de (imidazol-5-il)metil-2-quinlinona como inhibidores de la proliferacion de celulas de musculos lisos.
WO1999004794A1 (en) 1997-07-25 1999-02-04 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
DK1031563T3 (da) 1997-09-30 2006-05-08 Daiichi Seiyaku Co Sulfonylderivater
GB9726229D0 (en) 1997-12-12 1998-02-11 Zeneca Ltd Resolution of chiral amines
AU748064B2 (en) 1997-12-19 2002-05-30 Takeda Chemical Industries Ltd. Pharmaceutical composition for antagonizing CCR5 comprising anilide derivative
US6607799B1 (en) 1998-10-15 2003-08-19 3M Innovative Properties Company Surgical dressing with delivery system and method of manufacture
US6635278B1 (en) 1998-12-15 2003-10-21 Gilead Sciences, Inc. Pharmaceutical formulations
US6365583B1 (en) 1999-02-02 2002-04-02 Anormed, Inc. Methods to enhance white blood cell count
MXPA01009674A (es) 1999-03-24 2003-07-21 Anormed Inc Compuestos heterociclicos que se unen a receptores de quimiocina.
US6245799B1 (en) 1999-11-08 2001-06-12 American Home Products Corp [(Indol-3-yl)-cycloalkyl]-3-substituted azetidines for the treatment of central nervous system disorders
US6602872B1 (en) 1999-12-13 2003-08-05 Merck & Co., Inc. Substituted pyridazines having cytokine inhibitory activity
US6683192B2 (en) 2000-03-30 2004-01-27 Curis, Inc. Small organic molecule regulators of cell proliferation
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
HUP0301094A2 (hu) 2000-09-15 2003-09-29 Anormed Inc. Kemonikinreceptorhoz kötżdż heterociklusos vegyületek, e vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk
US6734191B2 (en) 2000-09-15 2004-05-11 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
AU2001291569B2 (en) 2000-09-15 2007-07-26 Anormed Inc. Chemokine receptor binding heterocyclic compounds
CN1575177A (zh) 2000-12-11 2005-02-02 图拉里克公司 Cxcr3拮抗剂
US6878714B2 (en) 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
GB0107228D0 (en) 2001-03-22 2001-05-16 Astrazeneca Ab Chemical compounds
DE60217322T2 (de) 2001-04-27 2007-10-04 Zenyaku Kogyo K.K. Heterocyclische verbindung und antitumormittel, das diese als wirkstoff enthält
US6794379B2 (en) 2001-06-06 2004-09-21 Tularik Inc. CXCR3 antagonists
CN102302493B (zh) 2001-07-31 2015-08-12 健赞股份有限公司 活化祖细胞/干细胞的方法
US7169750B2 (en) 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
US8178123B2 (en) 2001-08-29 2012-05-15 Femina Pharma Incorporated Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration
US20030055876A1 (en) * 2001-08-29 2003-03-20 Aravinda Korala Printing web content from self-service kiosks
BR0212443A (pt) 2001-09-12 2005-03-15 Anormed Inc Sìntese de anéis bicìclicos fundidos, amino substituìdos enanciomericamente puros
US7354932B2 (en) * 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
AU2002357379A1 (en) * 2001-12-21 2003-07-15 Anormed Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
US7491544B2 (en) 2002-05-20 2009-02-17 New York University Chiral piperidine and quinucledine ligands
DK1536827T3 (da) 2002-08-14 2009-04-20 Silence Therapeutics Ag Anvendelse af proteinkinase N-beta
WO2004052862A1 (ja) 2002-12-10 2004-06-24 Ono Pharmaceutical Co., Ltd. 含窒素複素環化合物およびその医薬用途
EA012240B1 (ru) 2003-04-03 2009-08-28 Семафор Фармасьютикалз, Инк. Пролекарства ингибиторов киназы pi-3
EP1613613B1 (en) 2003-04-11 2021-06-02 Genzyme Corporation Cxcr4 chemokine receptor binding compounds
US7501518B2 (en) 2003-04-22 2009-03-10 Genzyme Corporation Methods of making 2,6-diaryl piperidine derivatives
BRPI0409655B8 (pt) 2003-04-22 2021-05-25 Anormed Inc compostos heterocíclicos de ligação ao receptor para quimiocina com maior eficiência
PL1644363T3 (pl) 2003-05-30 2012-07-31 Gemin X Pharmaceuticals Canada Inc Związki triheterocykliczne, kompozycje i metody leczenia raka
AU2004257167B2 (en) 2003-07-03 2012-03-29 The Trustees Of The University Of Pennsylvania Inhibition of Syk kinase expression
US7498346B2 (en) 2003-12-11 2009-03-03 Genzyme Corporation Chemokine receptor binding compounds
JP4870660B2 (ja) * 2004-03-15 2012-02-08 アノーメッド インコーポレイティド Ｃｘｃｒ４アンタゴニストの合成プロセス
EP1742936A2 (en) 2004-04-13 2007-01-17 Icagen, Inc. Polycyclic pyridines as potassium ion channel modulators
DE102004021716A1 (de) 2004-04-30 2005-12-01 Grünenthal GmbH Substituierte Imidazo[1,2-a]pyridin-Verbindungen und Arzneimittel enthaltend substituierte Imidazo[1,2-a]pyridin-Verbindungen
RS55551B1 (sr) 2004-05-13 2017-05-31 Icos Corp Hinazolinoni kao inhibitori humane fosfatidilinozitol 3-kinaze delta
US20080096861A1 (en) 2004-08-02 2008-04-24 Smithkline Beecham Corporation Chemical Compounds
WO2006023400A2 (en) 2004-08-16 2006-03-02 Smithkline Beecham Corporation Chemical compounds
EP1799671A4 (en) 2004-09-02 2009-06-10 Smithkline Beecham Corp CHEMICAL COMPOUNDS
US20080171740A1 (en) 2004-09-24 2008-07-17 Smithkline Beecham Corporation Chemical Compounds
TW200619206A (en) 2004-09-29 2006-06-16 Anormed Inc Chemokine-binding heterocyclic compound salts, and methods of use thereof
KR101278397B1 (ko) 2005-01-19 2013-06-25 리겔 파마슈티칼스, 인크. 2,4-피리미딘디아민 화합물의 전구약물 및 이의 용도
US20090093454A1 (en) 2005-03-04 2009-04-09 Kristjan Gudmundsson Chemical Compounds
NZ561609A (en) 2005-05-12 2010-03-26 Abbott Lab 3-((trifluoromethyl)sulfonyl)benzenesulfonamide and 3-((chloro(difluoro)methyl)sulfonyl)benzenesulfonamide apoptosis promoters
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
WO2007006408A2 (en) 2005-07-08 2007-01-18 Bayer Healthcare Ag Methods and kits for predicting and monitoring direct response to cancer therapy
EP1904501A2 (en) 2005-07-11 2008-04-02 Smithkline Beecham Corporation Chemical compounds
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
CN101277981B (zh) 2005-08-02 2014-07-09 英尼奥斯欧洲有限公司 二烯聚合反应
EP1951046B1 (en) 2005-08-19 2012-07-18 Genzyme Corporation Methods to enhance chemotherapy
US20080234318A1 (en) 2005-08-31 2008-09-25 Kristjan Gudmundsson Chemical Compounds
CN103819416A (zh) 2005-10-07 2014-05-28 埃克塞里艾克西斯公司 N-(3-氨基-喹喔啉-2-基)-磺酰胺衍生物及其作为磷脂酰肌醇3-激酶抑制剂的用途
HUE028987T2 (en) 2005-11-01 2017-01-30 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
WO2007058322A1 (ja) 2005-11-18 2007-05-24 Ono Pharmaceutical Co., Ltd. 塩基性基を含有する化合物およびその用途
AR063656A1 (es) 2005-11-30 2009-02-11 Schering Corp Composiciones que comprenden una combinacion de antagonistas de ccr5 y cxcr4
EP2343298B9 (en) 2005-12-13 2020-05-06 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
JP2009524689A (ja) 2006-01-25 2009-07-02 スミスクライン ビーチャム コーポレーション 化合物
AR059197A1 (es) 2006-01-25 2008-03-19 Smithkline Beecham Corp Derivados de indazolo piridina para el tratamiento de hiv
GB0605786D0 (en) 2006-03-22 2006-05-03 Glaxo Group Ltd Compounds
AU2007246793B2 (en) 2006-04-26 2013-02-07 F. Hoffmann-La Roche Ag Thieno [3, 2-D] pyrimidine derivative useful as PI3K inhibitor
WO2007130373A2 (en) 2006-05-01 2007-11-15 Capricorn Pharma, Inc. Novel triptan formulations and methods for making them
AU2007258907A1 (en) 2006-06-12 2007-12-21 Pfizer Products Inc. CCR5 antagonist for enhancing immune reconstitution and treating opportunistic infection in HIV patients
TWI482772B (zh) 2006-08-21 2015-05-01 Astrazeneca Ab 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物
ES2585902T3 (es) 2006-09-22 2016-10-10 Pharmacyclics Llc Inhibidores de tirosina cinasa de Bruton
DK2152701T3 (en) 2007-03-12 2016-02-15 Ym Biosciences Australia Pty Phenylaminopyrimidinforbindelser and uses thereof
WO2008118802A1 (en) 2007-03-23 2008-10-02 Regents Of The University Of Minnesota Therapeutic compounds
WO2008141239A1 (en) 2007-05-10 2008-11-20 Acadia Pharmaceuticals Inc. Imidazol [1,2-a] pyridines and related compounds with activity at cannabinoid cb2 receptors
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
WO2009026251A1 (en) 2007-08-17 2009-02-26 The General Hospital Corporation Detecting ions and measuring ion concentrations
US9101628B2 (en) 2007-09-18 2015-08-11 The Board Of Trustees Of The Leland Stanford Junior University Methods and composition of treating a flaviviridae family viral infection
MY165582A (en) 2008-03-11 2018-04-05 Incyte Holdings Corp Azetidine and cyclobutane derivatives as jak inhibitors
US20110262386A1 (en) 2008-03-20 2011-10-27 Carolus Therpeutics, Inc. Methods of treating inflammation
EP2664618A3 (en) 2008-03-28 2014-05-07 Altiris Therapeutics Chemokine receptor modulators
WO2009151910A2 (en) 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
JP2010016628A (ja) 2008-07-03 2010-01-21 Canon Inc 画像処理装置及び画像処理方法
SG172060A1 (en) 2008-12-09 2011-07-28 Gilead Sciences Inc Modulators of toll-like receptors
WO2011036270A1 (en) 2009-09-28 2011-03-31 Kerry Group Services International Limited Pharmaceutical composition
CA2706292A1 (en) 2010-05-28 2011-11-28 Pharmascience Inc. A stable pharmaceutical formulation comprising telmisartan and hydrochlorothiazide
US20110293686A1 (en) 2010-05-28 2011-12-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-viral compositions and methods for administration
US9155723B2 (en) 2010-06-28 2015-10-13 The General Hospital Corporation Anti-CXCR4 as a sensitizer to cancer therapeutics
GB201017345D0 (en) 2010-10-14 2010-11-24 Proximagen Ltd Receptor antagonists
US9267934B2 (en) 2010-10-26 2016-02-23 University Of South Alabama Methods and compositions for ameliorating pancreatic cancer
US8969381B2 (en) 2010-12-03 2015-03-03 Emory University Chemokine CXCR4 receptor modulators and used related thereto
JP6076913B2 (ja) 2010-12-07 2017-02-08 ドレクセル ユニバーシティ 癌からの転移を阻害する方法
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
JP6087836B2 (ja) 2011-01-11 2017-03-01 ディメリックス バイオサイエンス プロプライアタリー リミテッド 併用療法
KR20210094672A (ko) 2011-05-16 2021-07-29 젠자임 코포레이션 Ｃｘｃｒ４ 길항제의 용도
AR087364A1 (es) 2011-07-29 2014-03-19 Pf Medicament Anticuerpo anti-cxcr4 y su uso para la deteccion y dianostico de canceres
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
WO2013106732A1 (en) 2012-01-12 2013-07-18 Gilead Sciences, Inc. Pharmaceutical compositions and methods for their preparation
WO2014082083A1 (en) 2012-11-26 2014-05-30 Caris Science, Inc. Biomarker compositions and methods
US10064826B2 (en) 2013-03-15 2018-09-04 Navinta, Llc Direct compression and dry granulation processes for preparing carglumic acid tablets having less impurities than those produced by wet granulation process
EP3473299A1 (en) 2013-06-05 2019-04-24 Salk Institute for Biological Studies Vitamin d receptor agonists to treat diseases involving cxcl12 activity
EP3030322A2 (en) 2013-08-05 2016-06-15 Cambridge Enterprise Limited Inhibition of cxcr4 signaling in cancer immunotherapy
EP3038601B1 (en) 2013-08-27 2020-04-08 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
AU2014318614B2 (en) 2013-09-12 2021-01-07 Dana-Farber Cancer Institute Inc. Methods for evaluating and treating Waldenstrom's macroglobulinemia
JP2016540042A (ja) 2013-11-05 2016-12-22 コグネート バイオサービシズ， インコーポレイテッド がんを処置するためのチェックポイント阻害剤および治療薬の組合せ
US10280183B2 (en) 2014-03-18 2019-05-07 The Research Foundation For The State University Of New York Therapeutic agent for treating tumors
SG11201607705XA (en) 2014-03-19 2016-10-28 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
US10450293B2 (en) 2014-05-16 2019-10-22 Emory University Chemokine CXCR4 and CCR5 receptor modulators and uses related thereto
US9394305B2 (en) 2014-06-23 2016-07-19 Dr. Reddy's Laboratories Ltd. Substituted imidazo[1,2-a]pyridine compounds as tropomyosin receptor kinase a (TrkA) inhibitors
PT3169341T (pt) 2014-07-16 2019-09-09 Transgene Sa Vírus oncolítico para a expressão de moduladores de pontos de controlo imunitário
EP3229817A4 (en) 2014-12-12 2018-06-20 Commonwealth Scientific and Industrial Research Organisation Dislodgement and release of hsc using alpha 9 integrin antagonist and cxcr4 antagonist
US20180133327A1 (en) 2015-03-16 2018-05-17 Amal Therapeutics Sa Cell Penetrating Peptides and Complexes Comprising the Same
JP2018516969A (ja) 2015-06-12 2018-06-28 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｐｄ−１およびｃｘｃｒ４シグナル伝達経路の組合せ遮断による癌の処置
CN114230571B (zh) 2015-09-14 2025-07-08 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
US10379661B2 (en) 2015-09-25 2019-08-13 Samsung Electronics Co., Ltd. Coordinate measuring apparatus and coordinate measuring system having the same
CA3008272A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
JP6958820B2 (ja) 2015-12-14 2021-11-02 エックス４ ファーマシューティカルズ， インコーポレイテッド がんを処置する方法
JP7055380B2 (ja) 2015-12-22 2022-04-18 エックス４ ファーマシューティカルズ， インコーポレイテッド 免疫不全疾患を処置するための方法
EP3405203A4 (en) 2016-01-22 2019-07-24 X4 Pharmaceuticals, Inc. METHOD FOR THE TREATMENT OF CANCER
US11337969B2 (en) 2016-04-08 2022-05-24 X4 Pharmaceuticals, Inc. Methods for treating cancer
CN109311989A (zh) 2016-04-14 2019-02-05 创新微技术公司 在癌症疗法的治疗决定中的pd-l1表达的应用方法
WO2017189999A1 (en) 2016-04-29 2017-11-02 Dana-Farber Cancer Institute, Inc. Hck as a therapeutic target in myd88 mutated diseases
CN116554168B (zh) 2016-06-21 2025-09-23 X4制药有限公司 Cxcr4抑制剂及其用途
WO2017223229A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
CN109641838A (zh) 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
JP2020525427A (ja) 2017-06-21 2020-08-27 エックス４ ファーマシューティカルズ， インコーポレイテッド 癌を処置するための方法
US20210349099A1 (en) 2017-11-07 2021-11-11 X4 Pharmaceuticals, Inc. Cancer biomarkers and methods of use thereof
CA3085763A1 (en) 2017-12-19 2019-06-27 X4 Pharmaceuticals, Inc. Acyclic cxcr4 inhibitors and uses thereof
EP3775877A4 (en) 2018-04-13 2021-12-22 X4 Pharmaceuticals, Inc. SERIAL CANCER BIOMARKERS AND THEIR METHODS OF USE
US10548889B1 (en) * 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
CN210928127U (zh) 2019-10-23 2020-07-03 奥特斯(中国)有限公司 部件承载件

Also Published As

Publication number Publication date
JP7525903B2 (ja) 2024-07-31
KR20210095118A (ko) 2021-07-30
JP2021535146A (ja) 2021-12-16
US20200253953A1 (en) 2020-08-13
US20220008410A1 (en) 2022-01-13
BR112021003467A2 (pt) 2021-05-18
US10548889B1 (en) 2020-02-04
US11672793B2 (en) 2023-06-13
KR102908092B1 (ko) 2026-01-07
WO2020047410A1 (en) 2020-03-05
CN112839649A (zh) 2021-05-25
US12115156B2 (en) 2024-10-15
EA202190377A9 (ru) 2021-08-09
IL281082A (en) 2021-04-29
US11045461B2 (en) 2021-06-29
US20250228843A1 (en) 2025-07-17
AU2019328530A1 (en) 2021-04-01
SG11202101814RA (en) 2021-03-30
EA202190377A1 (ru) 2021-07-22
JP2024138443A (ja) 2024-10-08
EP3843720A1 (en) 2021-07-07
CA3110735A1 (en) 2020-03-05
AU2019328530B2 (en) 2025-02-27
US20240058322A1 (en) 2024-02-22
EP3843720A4 (en) 2022-07-27

Similar Documents

Publication Publication Date Title
MX2021002180A (es) Composiciones de inhibidores del receptor de quimiocina c-x-c tipo 4 (cxcr4) y metodos de preparacion y uso.
MX2025003987A (es) Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos
MX2020011562A (es) Agonistas del receptor de la hormona tiroidea y usos de los mismos.
MY208549A (en) Parp1 inhibitors
MY205416A (en) Tyk2 inhibitors and uses thereof
EP4344706A3 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
WO2018013918A3 (en) Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
PH12022550165A1 (en) Interleukin-2 agents and uses thereof
PH12021550558A1 (en) Modulators of pnpla3 expression
PH12019502174A1 (en) Modulators of pcsk9 expression
MX2020009942A (es) Compuestos y usos de los mismos.
MX2019008124A (es) Metodos para el tratamiento de trastornos neurologicos.
MX2025003294A (es) Moduladores de la expresion de apol1
MX2020007369A (es) Moduladores de la expresion de dnm2.
MX2020007555A (es) Anticuerpos potenciadores del factor h y usos de los mismos.
MX2022007285A (es) Compuestos, polimeros, dispositivos y usos de los mismos.
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
PH12021550121A1 (en) Methods of treating hfpef employing dapagliflozin and compositions comprising the same
MX2020010721A (es) Moduladores de la expresion de ezh2.
PH12021551053A1 (en) Modulators of irf5 expression
MX2022006312A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos.
MX2021014987A (es) Composiciones farmaceuticas de liberacion modificada de huperzina y metodos para usarlas.
MX2023008839A (es) Composicion de liberacion tardia de linaclotida para uso en el tratamiento de trastornos gastrointestinales.
JOP20210107A1 (ar) مضمنات التعبير عن foxp3
ZA202002480B (en) Methods for treating or preventing asthma by administering an il-4r antagonist